Carotid atherosclerosis
Conditions
Interventions
Treatment group :Tongnaoyin with basic therapy and atorvastatin
Control group :basic therapy and atorvastatin
Sponsors
Jiangsu Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Aged 40 to 75 years; 2.No patients with cerebral hemorrhage or brain tumor were found by CT or MRI of the head; 3.Patients showed vulnerable plaque through carotid artery ultrasound and carotid artery contrast-enhanced ultrasound examination, or suspected to be vulnerable plaque requiring OCT. 4.Accept DSA examination and meet OCT carotid atherosclerosis vulnerable plaque; 5.Carotid artery lumen stenosis between 50%-70%; 6.Combined with the tongue veins,TCM syndrome differentiation belongs to Phlegm and Blood Stasis Syndrome; 7.Patients who have good compliance, agree to participate in the trial, and sign an informed consent form;
Exclusion criteria
Exclusion criteria: 1.There are clear contraindications to the use of antiplatelet drugs; 2.Allergies, such as those with a history of allergies to two or more drugs or foods, those who have been allergic to statins, Chinese patent medicines containing leeches, or suspected of allergies to leeches; 3.Abnormal liver and kidney function or severely elevated muscle enzymes (ALT, AST> 1.5 times the upper limit of normal, Cr> upper limit of normal); 4.Patients with severe gastrointestinal diseases such as stomach and duodenal ulcers and perforation, which affect the absorption of drugs; 5.Have serious primary heart, liver, lung, kidney, blood or serious diseases that affect their survival, such as tumor or AIDS; 6.Patients with a history of mental illness or disability; 7.Other lesions that, in the investigator's judgment, reduce the likelihood of inclusion or complicate inclusion, such as frequent changes in the work environment, may lead to loss of follow-up; 8.Patients who are participating in clinical observation of other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stability of plaque; | — |
Secondary
| Measure | Time frame |
|---|---|
| Traditional Chinese Medicine (TCM) syndrome efficacy;Acute event rate of ischemic cerebrovascular disease; | — |
Countries
China
Contacts
Public ContactWu Minghua
Jiangsu Provincial Hospital of Chinese Medicine
Outcome results
None listed